Parabolic Drugs IPO : Finally subscribed 1.04 times

by khalid on 18/06/2010 · 0 comments

Parabolic Drugs engaged in the manufacturing, including contract manufacturing, of APIs and API intermediates for the domestic market as well as for exports to international markets. The IPO of Parabolic Drugs Limited has received a minimal response from the investors with the final oversubscription figure nearing to just about 1.04 times on an overall basis. All the three categories of investors have shown least support. There was a reservation for employees but they subscribed only 0.11 times.

The category-wise subscription status of Parabolic Drugs Limited on closing day is given below:-

QIB : 1.48 Times
Non-Institutional Investors : 1.20 Times
Retail Investors : 0.40 Times
Employee Reservations : 0.11 times.
Overall : 1.24 Times

The proceeds of the IPO will be used by the company for its multi-purpose block III at Derabassi; Sterile cephalosporin plant at Derabassi; establishment of Chachrauli plant; custom synthesis & manufacturing site II at IT Park, Panchkula and repayment / prepayment of identified loan facilities.

The equity shares of the company are proposed to be listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Issue Detail:-
Issue Open : 14th Jun 2010 – 17th Jun 2010
Issue Type : 100% Book Built Issue IPO
Issue Size : Equity Shares of Rs 10 each
Issue Size : Rs. 200 Crores
Face Value : Rs 10 Per Equity Share
Issue Price : Rs. 75 – Rs. 85 Per Equity Share
Market Lot : 80 shares
Minimum Order Quantity : 80 shares
Listing At : BSE, NSE

Related Posts Plugin for WordPress, Blogger...

Leave a Comment

Previous post:

Next post: